Kineta KOL Event on KVA12123: VISTA as an Immuno-Oncology Target
About The Event
Watch the replay from the virtual KOL event with Kineta, featuring immunology expert Michael A. Curran, PhD (MD Anderson Cancer Center Department of Immunology) who discussed challenges in the current immuno-oncology landscape, along with the potential for VISTA blocking immunotherapy to address the problem of immunosuppression in the tumor microenvironment (TME), followed by a Fireside Chat with clinical oncology expert Patricia LoRusso, DO (Yale School of Medicine Cancer Center) on conducting clinical trials with novel immunotherapies to treat cancer.
Kineta’s leadership provided an update on its lead program KVA12123, a novel anti-VISTA monoclonal antibody, as a treatment for patients with advanced solid tumors. Kineta recently initiated a Phase 1/Phase 2 clinical study to investigate KVA12123 alone and in combination with pembrolizumab, Merck’s anti-PD-1 therapy.
A question and answer session followed the formal presentations.